Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
US THROMBOTIC MICROANGIOPATHY ALLIANCE
🇺🇸
United States
Country
🇺🇸
United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors
Not yet recruiting
Conditions
Immune Thrombotic Thrombocytopenia
Interventions
Drug: Caplacizumab
Subscribe
First Posted Date
2024-04-10
Last Posted Date
2024-11-13
Lead Sponsor
US Thrombotic Microangiopathy Alliance
Target Recruit Count
116
Registration Number
NCT06358703
Locations
🇺🇸
USTMA, Groveport, Ohio, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy